Albumin Excipient Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Human Serum Albumin is the fastest growing segment, North America is the largest market globally

The Global Albumin Excipient Market, valued at USD 4.98 Billion in 2024, is projected to experience a CAGR of 8.01% to reach USD 7.91 Billion by 2030. Albumin excipient is a highly purified protein, typically derived from human plasma or engineered recombinantly, utilized in pharmaceutical formulations as an inactive ingredient. Its primary functions include stabilizing active drug components, enhancing solubility, prolonging product shelf-life, and serving as a crucial element in cell culture media, vaccine production, and advanced drug delivery systems. The market's expansion is significantly driven by the escalating global demand for biopharmaceuticals and biologics, an increasing incidence of chronic diseases necessitating intravenous therapies, and continuous technological advancements in albumin production and purification processes.

Key Market Drivers

The global albumin excipient market is significantly propelled by the increasing demand for biopharmaceuticals and biologics, which rely heavily on albumin for stabilization and enhanced delivery. As the pharmaceutical industry increasingly focuses on complex protein-based therapies, albumin's unique properties as a non-immunogenic and effective stabilizer become indispensable. For example, according to the FDA's Center for Drug Evaluation and Research (CDER), in 2024, biologics accounted for 32% of all new drug approvals, a notable increase from the 28% average over the prior six years. This expanding pipeline and approval rate directly translate into a greater need for high-quality albumin excipients to ensure the safety, efficacy, and shelf-life of these advanced therapeutic products.

Key Market Challenges

The challenging factor for the Global Albumin Excipient Market is the inherently high production costs associated with both plasma-derived and recombinant albumin manufacturing. This significant impediment stems from the complex and resource-intensive processes required for both sources. For plasma-derived albumin, extensive collection networks, rigorous purification, and stringent safety testing contribute substantially to expenses. Similarly, recombinant albumin manufacturing necessitates sophisticated biotechnological processes, specialized equipment, and considerable research and development investments. These factors collectively drive up the cost of the final excipient.

Key Market Trends

The increasing adoption of recombinant albumin excipients addresses critical supply and safety considerations. Unlike plasma-derived albumin, recombinant alternatives offer enhanced consistency, a reduced risk of viral contamination, and overcome the ethical and supply chain challenges associated with human plasma sourcing. This shift is becoming increasingly necessary; according to the International Plasma and Fractionation Association (IPFA) and European Blood Alliance (EBA) symposium proceedings in August 2025, the European Medicines Agency anticipated plasma shortages to affect 14 European countries in 2024, highlighting the persistent supply challenges for plasma-derived products.

Key Market Players Profiled:

• Albumin Therapeutics LLC
• Biotest AG
• CSL Limited
• HiMedia Laboratories
• Medxbio Pte Ltd.
• Octapharma AG
• RayBiotech Inc
• SeraCare (LGC Clinical Diagnostics, Inc.)
• Sigma-Aldrich (Merck KGaA)
• LFB USA, Inc.

Report Scope:

In this report, the Global Albumin Excipient Market has been segmented into the following categories:

By Product:

• Human Serum Albumin
• Recombinant Albumin

By End user:

• Pharmaceutical and Biotechnology Industry
• Research Institutes
• Others

By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Albumin Excipient Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.